A Phase 1 trial of ALX-001, an investigational therapy for neurodegenerative conditions, has dosed the first patient with Parkinson’s disease. The clinical trial (NCT06309147) is assessing the safety of Allyx Therapeutics‘ ALX-001 versus a placebo when given twice a day at either 50 mg or 100 mg for…
News
Having difficulty recognizing and describing emotions may be associated with cognitive issues and with mood disorders such as depression, apathy, and impulse control problems in people with Parkinson’s disease, a review study suggests. As a result, the condition, called alexithymia, or emotional blindness, may reduce patients’ health-related quality of…
The brain weakens unused neural connections in the striatum, a region involved in motor control and decision-making, through a nitric oxide-dependent mechanism that appears to be disrupted in Parkinson’s disease, a study in mice suggests. According to the researchers, these findings reveal some of the molecular mechanisms underlying the…
Having acute kidney injury increases the risk of developing dementia, including Parkinson’s disease with dementia, according to a study that suggests that people with kidney damage may benefit from close monitoring for early detection of cognitive decline. “Identifying acute kidney injury as a risk factor for dementia can lead…
GT-02287, an oral small molecule from Gain Therapeutics, was found to be safe and well tolerated in healthy volunteers. It was also able to reach its target area, the brain, showing it has potential as a treatment for Parkinson’s disease linked to the GBA gene. The company plans…
The U.S. Food and Drug Administration (FDA) has again cleared Rebrain’s OptimMRI software, this time including a new machine learning model to assist in targeting specific brain regions for lesioning techniques such as MR-guided focused ultrasound and radiosurgery. Lesioning techniques involve the destruction of small areas of abnormal brain…
The gut microbiome of people with Parkinson’s disease exhibits substantial compositional and functional shifts relative to that of healthy individuals, with some of these changes linked to a faster progression of motor issues over time, according to a new study. “The [Parkinson’s disease] microbiome is functionally…
This fall, the Tampa Jewish Community Centers (JCCs) and Federation will host a symposium that aims to empower people with Parkinson’s disease by providing access to resources, the latest research, and opportunities to connect with the community. “The National Parkinson’s Project: Empowerment and Action” will be held…
Nearly 1 in 3 people in Japan with Parkinson’s disease also had sarcopenia, a progressive loss of muscle mass and strength, according to a new study. The researchers found that measuring the circumference of the calf, or the distance around the thickest part of the lower leg, was the…
The Parkinson’s Foundation said it awarded nearly $3 million in research grants to 33 recipients, aiming to accelerate innovative studies towards the development of potential new therapies, treatments, and ultimately a cure for Parkinson’s disease. “We are excited to fund these promising grant recipients as they develop more…
Recent Posts
- Blocking 2 proteins could slow Parkinson’s progression: Study
- How to minimize stress while traveling with Parkinson’s disease
- New PET tracer helps scientists ‘see’ Parkinson’s toxic protein clumps
- Tech duo to advance brain-penetrating drugs for CNS disorders
- New trial offers extended buntanetap access for people with Parkinson’s